Hi All,
Amylyx have announced revenue for the Dec Qtr. 108.42 million, bear in mind it was only approved in Sept 2023 and as outlined at the SGM RELYVRIO faces a few challengers. [There appears to only be around 3600 patients on it so far.]
Greater efficacy and less side effects would see a far greater take up, if MPL achieves these milestones.
Of those who started riluzole, 54 (15.4%) subsequently discontinued treatment. The most common reasons for discontinuation were gastrointestinal adverse effects (24.8%), including nausea, abdominal discomfort, constipation, and anorexia. Other adverse effects (including fatigue/malaise) accounted for 13.0%, deranged liver function 11.1%, and allergic reactions 9.3%. 13% discontinued due to ongoing ALS progression. In the remainder, the reason was unclear. Median time until discontinuation was 3 months for adverse effects and ALS progression (IQR 1.8–3.3 and 2.0–5.0, respectively) and 4.5 months for deranged liver function tests (IQR 2.5–6.0).
- Forums
- ASX - By Stock
- PAA
- Ann: FDA Provides Clear Feedback for ODD Approval
Ann: FDA Provides Clear Feedback for ODD Approval, page-264
-
- There are more pages in this discussion • 60 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
(20min delay)
|
|||||
Last
20.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $99.76M |
Open | High | Low | Value | Volume |
20.5¢ | 20.5¢ | 20.0¢ | $86.39K | 425.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 245685 | 20.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
20.5¢ | 204582 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 245685 | 0.200 |
6 | 229570 | 0.195 |
4 | 155324 | 0.190 |
11 | 505988 | 0.185 |
10 | 549536 | 0.180 |
Price($) | Vol. | No. |
---|---|---|
0.205 | 204582 | 4 |
0.210 | 302539 | 9 |
0.215 | 276995 | 8 |
0.220 | 734043 | 11 |
0.225 | 232889 | 5 |
Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
Featured News
PAA (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online